TradeOrgs
  • 🇮🇳 India
  • 🇺🇸 US
  • Screener
  • Backtest
  • Watchlist
  • Signals
  • Portfolio
  • Insights
  • Connect
Sign in
RELIANCE₹1,377.50▲ 14.60%TCS₹2,376.20▼ 3.44%HDFCBANK₹846.00▲ 18.82%ICICIBANK₹1,640.00▲ 18.75%INFY₹1,098.00▼ 2.89%HINDUNILVR₹2,052.50▲ 10.75%ITC₹299.10▲ 14.69%SBIN₹1,165.10▲ 19.66%BHARTIARTL₹2,161.70▲ 15.28%KOTAKBANK₹515.80▲ 16.62%LT₹4,209.10▲ 14.94%AXISBANK₹1,446.00▲ 16.99%ASIANPAINT₹2,608.30▲ 11.91%MARUTI₹14,011.00▲ 22.10%AAPL$342.56▲ 0.90%MSFT$484.52▼ 8.90%GOOGL$265.29▼ 22.04%AMZN$246.82▼ 6.02%NVDA$125.53▼ 42.01%META$560.84▼ 19.22%TSLA$345.82▼ 7.46%BRK-B$570.00▲ 5.59%JPM$310.53▼ 7.38%V$401.87▼ 1.16%
RELIANCE₹1,377.50▲ 14.60%TCS₹2,376.20▼ 3.44%HDFCBANK₹846.00▲ 18.82%ICICIBANK₹1,640.00▲ 18.75%INFY₹1,098.00▼ 2.89%HINDUNILVR₹2,052.50▲ 10.75%ITC₹299.10▲ 14.69%SBIN₹1,165.10▲ 19.66%BHARTIARTL₹2,161.70▲ 15.28%KOTAKBANK₹515.80▲ 16.62%LT₹4,209.10▲ 14.94%AXISBANK₹1,446.00▲ 16.99%ASIANPAINT₹2,608.30▲ 11.91%MARUTI₹14,011.00▲ 22.10%AAPL$342.56▲ 0.90%MSFT$484.52▼ 8.90%GOOGL$265.29▼ 22.04%AMZN$246.82▼ 6.02%NVDA$125.53▼ 42.01%META$560.84▼ 19.22%TSLA$345.82▼ 7.46%BRK-B$570.00▲ 5.59%JPM$310.53▼ 7.38%V$401.87▼ 1.16%

TradeOrgs shows market information and analyzes your own trading history. It does not place trades and is not investment advice.

Prices and listings are for information only. We are read-only against your broker account.

Technical signals (RSI, MACD, etc.) are educational readouts of public indicators — not recommendations.

Privacy Policy·© 2026 TradeOrgs

← US stocks

🇺🇸ABUS

Arbutus Biopharma Corporation - Common Stock

NASDAQ
$4.12
▼ $0.12 (-2.7%)
Live· just now
delayed feed · not for order timing

Price history · 20-day (cyan) / 50-day (purple) avg

as of 19 Nov 2026
H $5.45L $3.59-5.4%
$5.45$5.08$4.71$4.33$3.96$3.59$4.11
RSI (14)
Intraday · 15-minNeutral+10RSI 52UptrendMACD Bearishfor day-trading context — not advice

Technical signal

Sell-35
RSI (14)50
oversold 30overbought 70
Trend
Downtrend
MACD
Bullish
Bollinger
Within bands
vs 20-day
above
vs 50-day
below
vs 200-day
below
Support
$3.59
Resistance
$4.38
  • Price is below its 50-day average (medium-term weakness).

Educational technical indicators — not investment advice. TradeOrgs does not place trades.

Signal backtest · 2026-02-18 → 2026-11-19

Strategy return
-31.1%
Buy & hold
-0.4%
Trades
12
Win rate
8%

$100,000.00 invested would be worth $68,898.48 (-31.1%) · Full backtester →

Hypothetical: go long when the signal turns Buy, exit when it turns Sell. Past indicator behavior is not a prediction — educational only, not advice.

About Arbutus Biopharma Corporation· Biotechnology

source: yahoo

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.

Sector
Healthcare
Industry
Biotechnology
Employees
19
Headquarters
Warminster, United States
www.arbutusbio.com ↗

Fundamentals

source: yahoo
Market cap
$616.24M
P/E
3.6
P/B
9.3
EPS
$1.12
Div yield
0.0%
Profit margin
121.2%
ROE
269.6%
Debt / Equity
0.04
Beta
0.81
52-week range
$3.50 – $5.45
52-week low · $3.5032% of rangehigh · $5.45

Fundamental data is informational only — not investment advice.

Recent news

News sentiment:▲ Positive1↑ · 0↓ · 7–
  • Could Expanded Patent Lawsuits Change The Bull Case For BioNTech (BNTX)?— Neutral
    Simply Wall St. · 13 Nov 2026
  • BioNTech (BNTX) Dropped, So What Is Driving Attention Now?— Neutral
    Simply Wall St. · 13 Nov 2026
  • Arbutus: Q3 Earnings Snapshot— Neutral
    Associated Press · 10 Nov 2026
  • Arbutus Reports Third Quarter 2026 Financial Results and Provides Corporate Update
— Neutral
GlobeNewswire · 10 Nov 2026
  • MRNA Q3 Earnings Beat on COVID Sales, Raises '26 Outlook, Stock Rises▲ Positive
    Zacks · 06 Nov 2026
  • Arbutus Says US Lifts Clinical Hold on AB-101 Hepatitis B Drug— Neutral
    MT Newswires · 22 Oct 2026
  • Sentiment is a keyword-based read of the headline — a rough signal, not advice.